This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsLet’s ConnectStock Hub

Example content

About ATTR-CMAbout

Learn about ATTR-CM and uncover the differences between hereditary and wild-type ATTR-CM

About ATTR-CMWhat is ATTR-CM?The different types of ATTR-CM

Menu

Close

DiagnosisDiagnosis

Example of description text sitting alongside header

Diagnosis of ATTR-CMSigns and symptomsClinical cluesFormal diagnosis
Emerging treatmentsEducational resourcesEducational resources

Explore a range of educational resources to support the diagnosis of ATTR-CM

Educational resourcesExpert VideosDownloadable ResourcesOn Demand Congresses
Support & ResourcesVideosMaterials

Click here for Vyndaqel®▼ (tafamidis) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening, under-recognised, and underdiagnosed condition that mostly affects older adults.1,2
​​​​​​​Navigate the site to increase your understanding of the causes of the disease, signs and symptoms, diagnostic tools, and current and emerging treatment strategies, which can help to reduce the delay in the diagnosis and subsequent treatment of this ultimately fatal disease.
You can also visit the Educational Resources section to sign up to a virtual event or watch an expert speaker video.

What is ATTR-CM?

Understand ATTR-CM and why it is underdiagnosed

Understand ATTR-CM Loading

The different types of ATTR-CM

Uncover the differences between hereditary and wild-type ATTR-CM

Uncover ATTR-CM Loading

Diagnosis of ATTR-CM

Learn about techniques used to diagnose ATTR-CM, such as endomyocardial biopsy and nuclear scintigraphy

Diagnose ATTR-CM Loading

Current standard of care and emerging treatment strategies

Learn about current and emerging therapies for ATTR-CM

Discover emerging therapies Loading

ATTR-CM Educational Resources

Explore educational resources surrounding ATTR-CM​​​​​​​

Explore educational resources Loading

Contact a Pfizer representative

An easier way to connect with a member of the Pfizer team

Contact us​​​​​​​ Loading

References:

Witteles RM, Bokhari S, Damy T et al.  Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Heart Fail. 2019; 7(8): 709–716Lane T, Fontana M, Martinez-Naharro A et al. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation. 2019; 140: 16–26
PP-VYN-GBR-0953. February 2022

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store


Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc


This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ


Copyright © 2021 Pfizer Limited. All rights reserved.


VAT registration number GB201048427

PP-PFE-GBR-3849. November 2021

Add indication message here. It can link a link,
and you can EMBOLDEN text

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?

You are now leaving PfizerPro
 

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

​​​​​​​Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
 
For UK Healthcare Professionals *

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes No
You are now leaving PfizerPro
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​